CD8A and neoplasm: However, therapeutic efficacy varies across tumor models; in the IFN-γ-resistant RVP3 model, this regimen shows limited enhancement of CD8+ tumor-infiltrating lymphocytes and pro-inflammatory cytokines, indicating an incomplete reversal of tumor-intrinsic immune escape mechanisms [186].